PULSE BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.9 USD | -9.21% |
|
-6.38% | -43.63% |
| May. 07 | Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
| May. 07 | Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | 0.7 | Sales 2023 | - | Capitalization | 674M |
|---|---|---|---|---|---|
| Net income 2022 | -58M | Net income 2023 | -42M | EV / Sales 2022 | 168,485,877 x |
| Net Debt 2022 | 14.82M | Net cash position 2023 | 35.22M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.61
x | P/E ratio 2023 |
-13.9
x | Employees | 61 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 29.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pulse Biosciences, Inc.
More recommendations
More press releases
| 1 day | -9.21% | ||
| 1 week | -6.38% | ||
| Current month | -6.38% | ||
| 1 month | -8.85% | ||
| 3 months | -19.77% | ||
| 6 months | +29.94% | ||
| Current year | -43.63% |
1 week
6.85
8.42
1 month
6.608.42
Current year
6.6012.22
1 year
3.7813.62
3 years
1.1829.16
5 years
1.1845.82
10 years
1.1845.82
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Danahy
CEO | Chief Executive Officer | 54 | 22-02-13 |
| Chief Tech/Sci/R&D Officer | - | 23-05-02 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Duggan
CHM | Chairman | 79 | 17-11-01 |
| Director/Board Member | 46 | 17-11-01 | |
Darrin Uecker
CTO | Chief Tech/Sci/R&D Officer | 59 | 15-09-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.36% | 4 M€ | -5.15% | - | |
| 0.00% | 0 M€ | +3.45% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 6.9 | -9.21% | 147,798 |
| 24-05-07 | 7.6 | -1.68% | 233,503 |
| 24-05-06 | 7.73 | -1.15% | 194,682 |
| 24-05-03 | 7.82 | -2.86% | 169,447 |
| 24-05-02 | 8.05 | +5.92% | 179,846 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotes
Pulse Biosciences, Inc. is a bioelectric medicine company. The Companyâs proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Companyâs Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Calendar
2024-06-05
- Annual General Meeting
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| -43.63% | 420M | |
| +8.07% | 219B | |
| +7.87% | 184B | |
| +12.75% | 138B | |
| -1.37% | 62.54B | |
| +4.88% | 52.22B | |
| +11.59% | 51.73B | |
| +2.71% | 41.4B | |
| +4.90% | 37.17B | |
| +23.75% | 31.76B |
- Stock Market
- Equities
- PLSE Stock